Advanced Growth-FlexV® Pro Height System
DIETARY SUPPLEMENT
A precise mixture of USP grade amino acids that is used by athletes to support workout programs aimed at building and toning muscles & growth.
Boosting The Effect
The solution to this dilemma would be to find a way to decrease the amount of arginine while increasing it's effectiveness. Fortunately, using another amino acid along with Arginine accomplishes both goals.
A precise mixture of USP grade amino acids that is used by athletes to support workout programs aimed at building and toning muscles and growth. Research states that Arginine / Ornithine play a role in the body's immune response, wound healing abilities and growth.
Quality Control - Product Safety - Capsule Type
VCAPS Technolgy (Vegetarian Capsules Approved by Vegetarian Society)
Halal, Kosher certified supplement with vegetable origin - Non-GMO, starch-free, preservative-free, gluten-free.
Growth-flexV® Pro (High Quality Dietary Supplement)
High Quality L-Arginine & L-Ornithine-HCL (Vcaps Technology Capsules). Helps the body to increase the production of growth hormones to help maintain good health. Specifically formulated to include the highest quality amino acids that are derived from Natural Food Based products
Each Tablet Contains:
L-Arginine Base
L-Ornithine HCL
Silicon Dioxide
Magnesium Stearate
It is best taken between meals, without food when the stomach is more acidic.
Safe Vcaps (Vegetable Capsules) -This product does not contain any: Hormones, sugars, artificial colours, flavors or preservatives.
Main Benefits:
Helps Induce the release of growth hormone in the body.
Required for a properly functioning immune system.
Helps healing and repairing skin and tissues.
Helpful for people recouping after workout.
Helps Improve bone strength and regeneration.
Sealed cap for your protection.
BoneBuilder Denmaks™ (High Quality Essential Minerals)
A truly balanced and synergistic blend of essential minerals. its major function is in building and maintaining bone development! BoneBuilder Denmaks™ encourages bone growth with an exclusive blend of nutrients. While other bone health products help to protect existing bone mass, our product helps to promote new bone growth. It does this by activating the cells within the bone remodelling process responsible for building new bone. Existing bone is strengthened and supported, while your bones’ rebuilding process should improve with consistent use.
Each Tablet Contains:
Elemental calcium (carbonate) (from oyster shells)
Elemental magnesium (from oxide)
Vitamin D (cholecalciferol)
Elemental zinc (from gluconate)
Vitamin D (cholecalciferol)
Non medicinal ingredients: Providone, sodium croscarmellose , microcrystalline cellulose, sucrose, magnesium stearate , colloidal silicon dioxide, hydroxypropyl methylcellulose , carnauba, ethanol, propylene glycol , methylene chloride, polyethylene glycol.
It is best taken between meals, without food when the stomach is more acidic.
Safe Vcaps (Vegetable Capsules) -This product does not contain any: Hormones, sugars, artificial colours, flavors or preservatives.
Main Benefits & Recommended For:
Balances Autonomic Nerve System and regulates secretion
Prevention of bone demineralization
Prevention of osteoporosis
Helps prevent bone resorption (loss).
Helps normal development and maintenance of bones, and to maintain good health.
Sealed cap for your protection.
Growth-FlexV® Pro Advanced Height System
(Height Increase & Bone Development Techniques).
Finally, with the Advanced Bone Development Techniques, there is a quick and easy way to permanently improve height in as little as 4-6 weeks
Dr. Tran's Key (Height Increase And Bone Development Techniques) help condition the spinal discs, ligament, blood vessels and enhances the nervous system's function.
Main Benefits And Recommended For:
Balances autonomic nerve system and regulates secretion
Helps to improve your current height and overall all posture
Rehabilitation of spinal discs and cartilages thickening
Helps regenerate bone growth and development
Helps to accelerate the functions of the body for faster growth
Improved flexibility, weight reduction and overall health
Quick fix height system
The problem (The good news, the solution)
Factors which stunt height growth
Growth plate and its fusion
The vertical growth diet
The six essential food groups to boost height growth
Medical height increase solutions
Non medical growth solutions
The secret to spine lengthening
Vertical growth for upper body
Advanced leg lengthening technique
Growth in joints, cartilages and discs
Level 1- Vertical growth system
Level 2- Advanced vertical growth system
100% Guaranteed results and satisfaction!)
A good Height and Posture is important not only for your personal appearance and attitude, but also for your overall health and physical well-being.
Having your bone and posture in great shape tends to make you feel great! How tall you “are" is often determined by the condition of your posture. Having a stiff back equals to feeling old regardless of age. After many years of research and development, Dr.Tran narrowed these Advanced Posture and Height Development Techniques to be the quickest and simplest ways to help reach your peak height. Some of these techniques are aimed for maintaining and rehabilitating the constant regeneration of spinal discs. Indeed the main reason for decreased body height is due to the degeneration of spinal discs....a condition which can be rehabilitated.
This "Advanced Posture & Height Rebuilding System" is what Dr.Tran recommends to most patients. The purpose of these techniques is also to help bring your body structure to a more vertical and proportional stage. As you get older, Dr.Tran's techniques will help you prevent your self from having a forward-slumping posture, height loss and even that stereotypical "old age" look. You will be surprised how much height is hidden in your slouched back and mal-posture.
A good Height and Posture is important not only for your personal appearance and attitude, but also for your overall health and physical well-being.
The statements on this website regarding all dietary supplements have not been approved by the Food & Drug Administration. These supplements are not intended to diagnose, treat, cure or prevent disease. Before beginning any new supplement or exercise program, please consult with your physician. Growth-flexV® Pro is a registered trademark of Sinotech Int Corp. This document may not be copied in part or full without express written permission from the publisher. All violations will be prosecuted to the fullest extent of the law.
_________________________________________________________________________________________
References...
Studies Research: and Opinion 7:475-481 1981
Journal of Parenteral and Enteral Nutrition 18:559-560 1994
Journal of Applied Physiology 64: 579-584 1988 References:
1. CHAPMAN IM, HARTMAN MI., PEZZOLI SS, et al, Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-1 negative feedback. J. Clin Endocrin Metab. 82: 2996-3004, 1997.
2. TATTERSALL R. A history of growth hormone. Horm Res. 46:236-47, 1996.
3. HEDNER E, LINDE A, NILSSON A. Systemically and locally administered growth hormone stimulates bone healing in combination with osteopromotive membranes: an experimental study in rats. J Bone Min Res. 11 (12):: 1952-60, 1996.
4. SAITO H, INOUE T, FUKATSU K., ET AL. Growth hormone and the immune response to bacterial infection. Horm Res. 45: 50-54, 1996.
5. ROEMMICH JN. ROGOL AD. Exercise and growth hormone: does one affect the other? J Pediatr 131: S75-80, 1997.
6. ISGAARD J., KUJACIC V., JENNISCHE E., ET AL. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Euro J Clin Invest. 27:517-25,1997. 7. POWELL DR., LIU F., BAKER BK, ET AL. Modulation of growth factors by growth hormone in children with chronic renal failure. Kidney Intl. 51: 1970-79, 1997.
8. LANES R., BUNCZLER P., ORTA N., ET AL. Changes in bone mineral density, growth velocity and renal function of prepubertal uremic children during growth hormone treatment. Horm Res. 46: 263-68, 1996.
9. VARA-THORBECK R., RUIZ-REQUENA E., GUERRERO-FERNANDEZ JA. Effects of human growth hormone on the catabolic state after surgical trauma. Horm Res. 45:55-60, 1996.
10. BOLLERSLEV J., MOLLER J., THOMAS S., ET AL. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency. Euro J Endocrin 135: 666-71, 1996.
11. HIRSCHFELD S. Use of human recombinant growth hormone and human recombinant insulin-like growth factor-1 in patients with human immunodeficiency virus infection. Horm Res. 46: 215-221, 1996.
12. KHORRAM O., LAUGHLIN GA., YEN SSC. Endocrine and metabolic effects of long-term administration of (NLE27) growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrin Metab. 82:1472-79, 1997.
13. JOHANNSSON G., GRIMBY G., SUNNERHAGE KS., ET AL. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrin Metab. 82: 2877-84, 1997.
14. RUDMAN D., ET AL., N Engl J Med. 1990; 323:1-61.
15. REYES AA., KARL IE., KLAR S., Role of arginine in health and renal disease. Am J Physiol. 267:F331-46, 1994.
16. LEVIN SR., KARAM JH., HANE S., ET AL., Enhancement of arginine-induced insulin secretion in man by prior administration of glucose. Diabetes. 20: 171-76, 1971.
17. CORPAS E., BLACKMAN MR., ROBERSON R., ET AL., Oral arginine-lysine does not increase growth hormone or insulin-like growth factor-1 in old men. J Gerontol. 48(4): M128-33, 1993.
18. MERIMEE TJ., RABINOWITZ D., FINEBERG SE., Arginine-initiated release of human growth hormone. N Engl J Med. 280(26): 1434-38, 1969.
19. BAUMAN WA., SPUNGEN AM., FLANAGAN S., ET AL., Blunted growth hormone response to intravenous arginine in subjects with a spinal cord injury. Horm Metab Res. 26: 152-56, 1994.
20. PROCOPIO M., MACCARIO M., GROTTOLI S., ET AL., Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine. Clin Endocrin.. 43:665-69, 1995.
21. GHIGO E., PROCOPIO M., BOFFANO GM., ET AL., Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. Metabolism. 41 (5): 560-63, 1992.
22. ISIDORI A., LO MONACO A., CAPPA M., A study of growth hormone release in man after oral administration of amino acids. Curr Med Res Opinion. 7(7):475-81, 1981.
23. JEEVANANDAM M., HOLADAY NJ., PETERSEN SR., Ornithine-a-Ketoglutarate (OKG) supplementation is more effective than its component salts in traumatized rats. J Nutr. 126:2141-50, 1996.
24. WERNERMAN J. HAMMARQVIST F., VON DER DECKEN A., ET AL. Orthinine -alpha-ketoglutarate improves skeletal muscle protein synthesis as assessed by ribosome analysis and nitrogen use after surgery. Ann Surg. 206(5): 674-78, 1985.
25. CYNOBER L., COUDRAY-LUCAS C., DE BANDT JP., ET AL., Action of orthinine-a-ketoglutarate, orthinine hydrochloride, and calcium a-ketoglutarate on plasma amino acid and hormonal patterns in healthy subjects. J Am Coll Nutr. 9(1): 2-12, 1990.
26. CYNOBER L. Can arginine and ornithine support gut function? Gut. (suppl 1): S42-S45,1994.
27. KRASSOWSKI J., ROUSSELL J., MAEDER E., ET AL., The effect of orthinine-a-ketoglutarate on insulin and glucagon secretion in normal subjects. Acta Endocrinologica. 98: 252-55, 1981.
28. LIEBERMAN SA., HOFFMAN AR., Growth hormone deficiency in adults: characteristics and response to growth hormone replacement. J Pediatr. 128: S58-60, 1996.
29. BESSET A., BONARDET A., RONDOUIN G., DESCOMPS B., AND PASASOUANT P. Increase in sleep related GH and Prl secretion after chronic arginine aspartate administration in man. Acta Endocrinologica. 1982;99:18-23.
---------------------------------------------------------------------------------------------------------------------------------------------------
1 Moncada, S. and Higgs, E. A. (1993) The L-arginine?itric oxide pathway. N. Engl. J. Med. 329, 2002012 Medline 1st Citation
2 Palmer, R. M. J., Ashton, D. S. and Moncada, S. (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (London) 333, 66466 Medline 1st Citation
3 Cooke, J. P. and Tsao, P. S. (1994) Is NO an anti-atherogenic molecule? Arterioscler. Thromb. 14, 65355 1st Citation
4 Creager, M. A., Cooke, J. P., Mendelson, M. E. et al. (1990) Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest. 86, 22834 Medline 1st Citation
5 Wolf, A., Zalpour, C., Theilmeier, G. et al. (1997) Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J. Am. Coll. Cardiol. 29, 47985 1st Citation 2nd 3rd
6 Wang, B. Y., Candipan, R. C., Arjomandi, M., Hsiun, P. T. C., Tsao, P. S. and Cooke, J. P. (1996) Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. J. Am. Coll. Cardiol. 28, 1573579 1st Citation 2nd
7 Tsao, P. S., Theilmeier, G., Singer, A. H., Leung, L. L. K. and Cooke, J. P. (1994) L-Arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler. Thromb. 14, 1529533 Medline 1st Citation 2nd
8 Rossitch, E. J., Alexander, E. D., Black, P. M. and Cooke, J. P. (1991) L-Arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J. Clin. Invest. 87, 1295299 Medline 1st Citation 2nd
9 Cooke, J. P., Singer, A. H., Tsao, P., Zera, P., Rowan, R. A. and Billingham, M. E. (1992) Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 90, 1168172 Medline 1st Citation 2nd
10 Creager, M. A., Gallagher, S. J., Girerd, X. J., Coleman, S. M., Dzau, V. J. and Cooke, J. P. (1992) L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. 90, 1248253 Medline 1st Citation 2nd
11 Drexler, H., Zeiher, A. M., Meinzer, K. and Just, H. (1991) Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet 338, 1546550 Medline 1st Citation 2nd
12 Clarkson, P., Adams, M. R., Powe, A. J. et al. (1996) Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J. Clin. Invest. 97, 1989994 Medline J. Clin. Invest. 1st Citation 2nd 3rd 4th 5th 6th 7th
13 Rector, T. S., Bank, A. J., Mullen, K. A. et al. (1996) Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 93, 2135141 Medline 1st Citation
14 Reyes, A. A., Karl, I. E. and Klahr, S. (1994) Role of arginine in health and in renal disease. Am. J. Physiol. 267, F331?346 Medline 1st Citation 2nd 3rd 4th
15 Chauhan, A., More, R., Mullins, P., Taylor, G., Petch, C. and Schofield, P. (1996) Aging-associated endothelial dysfunction in humans is reversed by L-arginine. J. Am. Coll. Cardiol. 28, 1796804 1st Citation
16 Pieper, G. M. (1998) Review of alterations in endothelial nitric oxide production in diabetes. Protective role of arginine on endothelial dysfunction. Hypertension 31, 1047060 Medline 1st Citation
17 Singer, A. H., Tsao, P. S., Wang, B. Y., Bloch, D. A. and Cooke, J. P. (1995) Discordant effects of dietary L-arginine on vascular structure and reactivity in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 25, 71016 Medline 1st Citation 2nd 3rd
18 Jeremy, R. W., McCarron, H. and Sullivan, D. (1996) Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilatation in the hypercholesterolemic rabbit. Response according to treatment duration, anatomic site, and sex. Circulation 94, 49806 Medline 1st Citation 2nd 3rd 4th 5th 6th 7th
19 Ignarro L. J., Gold M. E., Buga, G. M. et al. (1989) Basic polyamino acids rich in arginine, lysine, or ornithine cause both enhancement of and refractoriness to formation of endothelium-derived nitric oxide in pulmonary artery and vein. Circ. Res. 64, 31529 1st Citation
20 Cooke, J. P. (1997) Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 96, 37982 Medline 1st Citation 2nd
21 Maxwell, A. J. and Cooke, J. P. (1998) Cardiovascular effects of L-arginine. Curr. Opin. Nephrol. Hypertens. 7, 630 1st Citation 2nd
22 Visek, W. J. (1986) Arginine needs, physiological state and usual diets. A reevaluation. J. Nutr. 116, 366 1st Citation
23 Castillo, L., Chapman, T. E., Sanchez, M. et al. (1993) Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets. Proc. Natl. Acad. Sci. U.S.A. 90, 7749753 Medline 1st Citation 2nd
24 Castillo, L., Ajami, A., Branch, S. et al. (1994) Plasma arginine kinetics in adult man: response to an arginine-free diet. Metabolism 43, 11422 Medline 1st Citation
25 Castillo, L., Chapman, T. E., Yu, Y. M., Ajami, A. M., Burke, J. F. and Young, V. R. (1993) Dietary arginine uptake by the splanchnic region in adult humans. Am. J. Physiol. 265, E532?539 Medline 1st Citation
26 Souba, W. W. and Pacitti, A. J. (1992) How amino acids get into cells: mechanisms, models, menus, and mediators. J. Parenter. Enteral Nutr. 16, 56978 1st Citation 2nd
27 Schmidt, K., Klatt, P. and Mayer, B. (1993) Characterization of endothelial cell amino acid transport systems involved in the actions of nitric oxide synthase inhibitors. Mol. Pharmacol. 44, 61521 Medline Mol. Pharmacol. 1st Citation
28 Inoue, Y., Bode, B. P., Beck, D. J., Li, A. P., Bland, K. I. and Souba, W. W. (1993) Arginine transport in human liver. Ann. Surg. 218, 35063 1st Citation
29 Castillo, L., Sanchez, M., Chapman, T. E., Ajami, A. M., Burke, J. F. and Young, V. R. (1994) The plasma flux and oxidation rate of ornithine adaptively decline with restricted L-arginine intake. Proc. Natl. Acad. Sci. U.S.A. 91, 6393397 Medline 1st Citation
30 Morris, S. M. J. (1992) Regulation of enzymes of urea and arginine synthesis. Annu. Rev. Nutr. 12, 8101 Medline 1st Citation
31 Southern, L. L. and Baker, D. H. (1982) Performance and concentration of amino acids in plasma and urine of young pigs fed diets with excesses of either arginine or lysine. J. Animal Sci. 55, 85766 1st Citation
32 Young, J. A. and Freedman, S. B. (1971) Renal tubular transport of amino acids. Clin. Chem. 17, 24566 Medline 1st Citation
33 McAllister, R. J., Calver, A. L., Collier, J. et al. (1995) Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effect? Clin. Sci. 89, 18390 1st Citation 2nd 3rd
34 Kurz, S. and Harrison, D. G. (1997) Insulin and the arginine paradox. J. Clin. Invest. 99, 36970 Medline J. Clin. Invest. 1st Citation 2nd
35 Giugliano, D. R., Marfella, R., Verrazzo, G. et al. (1997) The vascular effects of L-arginine in humans. The role of endogenous insulin. J. Clin. Invest. 99, 43338 Medline 1st Citation 2nd 3rd
36 Xu, X. J., Li, Y. J. and Xiong, Y. (1994) Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci. 54, 75358 1st Citation
------------------------------------------------------------------------------------------------------------------------------------------------------
http://en.wikipedia.org/wiki/Nitric_oxide
http://www.clinsci.org/cs/096/0199/cs0960199.htm
Ornithine--Ketoglutarate (OKG) Supplementation Is More Effective than Its Component Salts in Traumatized Rats: Addition of an anabolic stimulus during nutritional support seems to be a reasonable adjunct to augment protein synthesis. Ornithine--ketoglutarate (OKG) has been used for this purpose in many pathological situations, but the mechanism of action is poorly understood.
Overall research data suggest that the mechanism of OKG action may be associated with increases in growth hormone and insulin, as well as the production of metabolites of ORN and KG. OKG has better metabolic benefits than its two components given separately in the nutritional support of injured rats. Ornithine alpha-ketoglutarate in nutritional support.
Ornithine alpha-ketoglutarate (OKG) is a salt formed of two molecules of ornithine and one molecule of alpha-ketoglutarate. OKG has been successfully used by the enteral and parenteral route in burn, traumatized, and surgical patients and in chronically malnourished subjects. According to the metabolic situation, OKG treatment decreases muscle protein catabolism and/or increases synthesis. In addition, OKG promotes wound healing. The mechanism of action of OKG is not fully understood, but the secretion of anabolic hormones (insulin, human growth hormone) and the synthesis of metabolites (glutamine, polyamines, arginine, ketoacids) may be involved.
Growth retardation in children receiving long-term total parenteral nutrition: effects of ornithine alpha-ketoglutarate: The effect of ornithine ketoglutarate (OKG) in reversing abnormal growth in six prepubertal children receiving total parenteral nutrition (TPN) for 5-10 y were evaluated in this study. This study demonstrates that OKG is associated with statural growth acceleration and increased IGF1 concentrations.
A pilot study of l-arginine supplementation on functional capacity in peripheral arterial disease: Peripheral arterial disease (PAD) impairs walking capacity and is often associated with a profound endothelial vasodilator dysfunction, characterized by reduced bioactivity and/or synthesis of endothelium-derived nitric oxide (NO). The results showed there was no significant difference observed in absolute claudication distance between the groups. However, a trend was observed for a greater increase in walking distance in the group treated with 3 g L-arginine daily, and there was a trend for an improvement in walking speed in patients treated with L-arginine. This pilot study provided data for safety, for power calculation and for dosing for the larger definitive trial that is now underway.
_________________________________________________________________________________________